Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

LYCABullishCorporate Developmentsnews

High materiality7/10

Lycia closes upsized IPO, raises $365 million for autoimmune programs

Oct 26, 2026, 4:26 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

A substantial cash infusion reduces financing risk, supports ongoing trials, and may lift near-term investor sentiment; however, upside depends on upcoming clinical data and potential dilution from future financings.

AI summary

What happened, with direct paths to the underlying reporting

Lycia Therapeutics announced the upsized closing of its IPO, raising about $365.1 million at $18 per share and listing LYCA on Nasdaq on Oct 23, 2026. The cash infusion strengthens its balance sheet and funds early-stage autoimmune and inflammatory programs, potentially extending clinical development runway.

Lycia upsizes IPO to 20.29M shares at $18, raising about $365.1M.
Includes 2.646M additional shares exercisable by underwriters.
Stock began trading Oct 23, 2026 on Nasdaq under LYCA.
Funds strengthen Lycia's balance sheet for autoimmune/inflammatory programs.
Company aims to advance clinical development with expanded liquidity.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.